Last updated on July 2019

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT)


Brief description of study

This is a global, randomized, double-blind, controlled study to evaluate the efficacy of bemarituzumab (FPA144) + mFOLFOX6 versus placebo + mFOLFOX6 in patients with FGFR2 selected Gastric Cancer (as determined by prospective IHC FGFR2b overexpression and/or a ctDNA blood assay demonstrating FGFR2 gene amplification)

Detailed Study Description

The main purpose of this study is to evaluate the efficacy of bemarituzumab (FPA144), which is a targeted antibody, in combination with modified FOLFOX6 compared to placebo in combination with modified FOLFOX6 in participants with Gastric Cancer as measured by overall survival.

Clinical Study Identifier: NCT03694522

Find a site near you

Start Over

Yale Cancer Center

New Haven, CT United States
  Connect »

University of Chicago

Chicago, IL United States
  Connect »

Oschsner Clinic Foundation

New Orleans, LA United States
  Connect »

Karmanos Cancer Institute

Detroit, MI United States
  Connect »

Tennessee Cancer Specialists

Knoxville, TN United States
  Connect »

Arlington Cancer Center

Arlington, TX United States
  Connect »

Ajou University Hospital

Suwon, Korea, Republic of
  Connect »

Dong-A University Hospital

Busan, Korea, Republic of
  Connect »

Kangbuk Samsung Hospital

Seoul, Korea, Republic of
  Connect »

Asan Medical Center

Seoul, Korea, Republic of
  Connect »

Sutter Medical Group

Sacramento, CA United States
  Connect »

Stony Brook Cancer Center

Stony Brook, NY United States
  Connect »

CH de l'Ardenne

Libramont, Belgium
  Connect »

CHU de Saint Etienne

Saint-Étienne, France
  Connect »

CHU de Saint Etienne

Saint-Étienne, France
  Connect »

AZ Sint Jan

Brugge, Belgium
  Connect »

CHU de Saint Etienne

Saint-Étienne, France
  Connect »

CHU de Saint Etienne

Saint-Étienne, France
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.